Design and baseline characteristics of the Soy Phytoestrogens As Replacement Estrogen (SPARE) study - A clinical trial of the effects of soy isoflavones in menopausal women

Silvina Levis, Nancy Strickman-Stein, Daniel R. Doerge, Jeffrey Krischer

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Following the results of the Women's Health Initiative, many women now decline estrogen replacement at the time of menopause and seek natural remedies that would treat menopausal symptoms and prevent bone loss and other long-term consequences of estrogen deficiency, but without adverse effects on the breast, uterus, and cardiovascular system. The results of most soy studies in this population have had limitations because of poor design, small sample size, or short duration. This report describes the study rationale, design, and procedures of the Soy Phytoestrogens As Replacement Estrogen (SPARE) study, which was designed to determine the efficacy of soy isoflavones in preventing spinal bone loss and menopausal symptoms in the initial years of menopause. Women ages 45 to 60 without osteoporosis and within 5 years from menopause were randomized to receive soy isoflavones 200 mg daily or placebo for 2 years. Participants have yearly measurements of spine and hip bone density, urinary phytoestrogens, and serum lipids, thyroid stimulating hormone, and estradiol. Menopausal symptoms, mood changes, depression, and quality of life are assessed annually. The SPARE study recruited 283 women, 66.1% were Hispanic white. With a large cohort, long duration, and large isoflavone dose, this trial will provide important, relevant, and currently unavailable information on the benefits of purified soy isoflavones in the prevention of bone loss and menopausal symptoms in the first 5 years of menopause. Given the high proportion of Hispanics participating in the study, the results of this trial will also be applicable to this minority group.

Original languageEnglish
Pages (from-to)293-302
Number of pages10
JournalContemporary Clinical Trials
Volume31
Issue number4
DOIs
StatePublished - Jul 1 2010

Fingerprint

Phytoestrogens
Estrogen Replacement Therapy
Isoflavones
Menopause
Clinical Trials
Hispanic Americans
Bone and Bones
Pelvic Bones
Minority Groups
Women's Health
Thyrotropin
Cardiovascular System
Sample Size
Bone Density
Osteoporosis
Uterus
Estradiol
Estrogens
Breast
Spine

Keywords

  • Bone health
  • Isoflavones
  • Menopause
  • Osteoporosis
  • Soy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Design and baseline characteristics of the Soy Phytoestrogens As Replacement Estrogen (SPARE) study - A clinical trial of the effects of soy isoflavones in menopausal women. / Levis, Silvina; Strickman-Stein, Nancy; Doerge, Daniel R.; Krischer, Jeffrey.

In: Contemporary Clinical Trials, Vol. 31, No. 4, 01.07.2010, p. 293-302.

Research output: Contribution to journalArticle

@article{f69e51cc84fa41dfbdf3e31a7223cd21,
title = "Design and baseline characteristics of the Soy Phytoestrogens As Replacement Estrogen (SPARE) study - A clinical trial of the effects of soy isoflavones in menopausal women",
abstract = "Following the results of the Women's Health Initiative, many women now decline estrogen replacement at the time of menopause and seek natural remedies that would treat menopausal symptoms and prevent bone loss and other long-term consequences of estrogen deficiency, but without adverse effects on the breast, uterus, and cardiovascular system. The results of most soy studies in this population have had limitations because of poor design, small sample size, or short duration. This report describes the study rationale, design, and procedures of the Soy Phytoestrogens As Replacement Estrogen (SPARE) study, which was designed to determine the efficacy of soy isoflavones in preventing spinal bone loss and menopausal symptoms in the initial years of menopause. Women ages 45 to 60 without osteoporosis and within 5 years from menopause were randomized to receive soy isoflavones 200 mg daily or placebo for 2 years. Participants have yearly measurements of spine and hip bone density, urinary phytoestrogens, and serum lipids, thyroid stimulating hormone, and estradiol. Menopausal symptoms, mood changes, depression, and quality of life are assessed annually. The SPARE study recruited 283 women, 66.1{\%} were Hispanic white. With a large cohort, long duration, and large isoflavone dose, this trial will provide important, relevant, and currently unavailable information on the benefits of purified soy isoflavones in the prevention of bone loss and menopausal symptoms in the first 5 years of menopause. Given the high proportion of Hispanics participating in the study, the results of this trial will also be applicable to this minority group.",
keywords = "Bone health, Isoflavones, Menopause, Osteoporosis, Soy",
author = "Silvina Levis and Nancy Strickman-Stein and Doerge, {Daniel R.} and Jeffrey Krischer",
year = "2010",
month = "7",
day = "1",
doi = "10.1016/j.cct.2010.03.007",
language = "English",
volume = "31",
pages = "293--302",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Design and baseline characteristics of the Soy Phytoestrogens As Replacement Estrogen (SPARE) study - A clinical trial of the effects of soy isoflavones in menopausal women

AU - Levis, Silvina

AU - Strickman-Stein, Nancy

AU - Doerge, Daniel R.

AU - Krischer, Jeffrey

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Following the results of the Women's Health Initiative, many women now decline estrogen replacement at the time of menopause and seek natural remedies that would treat menopausal symptoms and prevent bone loss and other long-term consequences of estrogen deficiency, but without adverse effects on the breast, uterus, and cardiovascular system. The results of most soy studies in this population have had limitations because of poor design, small sample size, or short duration. This report describes the study rationale, design, and procedures of the Soy Phytoestrogens As Replacement Estrogen (SPARE) study, which was designed to determine the efficacy of soy isoflavones in preventing spinal bone loss and menopausal symptoms in the initial years of menopause. Women ages 45 to 60 without osteoporosis and within 5 years from menopause were randomized to receive soy isoflavones 200 mg daily or placebo for 2 years. Participants have yearly measurements of spine and hip bone density, urinary phytoestrogens, and serum lipids, thyroid stimulating hormone, and estradiol. Menopausal symptoms, mood changes, depression, and quality of life are assessed annually. The SPARE study recruited 283 women, 66.1% were Hispanic white. With a large cohort, long duration, and large isoflavone dose, this trial will provide important, relevant, and currently unavailable information on the benefits of purified soy isoflavones in the prevention of bone loss and menopausal symptoms in the first 5 years of menopause. Given the high proportion of Hispanics participating in the study, the results of this trial will also be applicable to this minority group.

AB - Following the results of the Women's Health Initiative, many women now decline estrogen replacement at the time of menopause and seek natural remedies that would treat menopausal symptoms and prevent bone loss and other long-term consequences of estrogen deficiency, but without adverse effects on the breast, uterus, and cardiovascular system. The results of most soy studies in this population have had limitations because of poor design, small sample size, or short duration. This report describes the study rationale, design, and procedures of the Soy Phytoestrogens As Replacement Estrogen (SPARE) study, which was designed to determine the efficacy of soy isoflavones in preventing spinal bone loss and menopausal symptoms in the initial years of menopause. Women ages 45 to 60 without osteoporosis and within 5 years from menopause were randomized to receive soy isoflavones 200 mg daily or placebo for 2 years. Participants have yearly measurements of spine and hip bone density, urinary phytoestrogens, and serum lipids, thyroid stimulating hormone, and estradiol. Menopausal symptoms, mood changes, depression, and quality of life are assessed annually. The SPARE study recruited 283 women, 66.1% were Hispanic white. With a large cohort, long duration, and large isoflavone dose, this trial will provide important, relevant, and currently unavailable information on the benefits of purified soy isoflavones in the prevention of bone loss and menopausal symptoms in the first 5 years of menopause. Given the high proportion of Hispanics participating in the study, the results of this trial will also be applicable to this minority group.

KW - Bone health

KW - Isoflavones

KW - Menopause

KW - Osteoporosis

KW - Soy

UR - http://www.scopus.com/inward/record.url?scp=77953544142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953544142&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2010.03.007

DO - 10.1016/j.cct.2010.03.007

M3 - Article

C2 - 20230914

AN - SCOPUS:77953544142

VL - 31

SP - 293

EP - 302

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

IS - 4

ER -